Phenotypes associated with this allele

• Allele Symbol: Tg(APPV717F)109Ili
• Allele Name: transgene insertion 109, Ivan Lieberburg
• Allele ID: MGI:2151935
• Summary: 20 genotypes

Jump to	Allelic Composition	Genetic Background	Genotype ID
cn1	Gsk3a^tm1.1Tac/Gsk3a^tm1.1Tac Tg(APPV717F)109Ili/0 Tg(Camk2a-cre)#Stl/0	involves: BALB/c * C57BL * C57BL/6NTac	MGI:5427914
cx2	Becn1^tm2.1Blev/Becn1^tm2.1Blev Tg(APPV717F)109Ili/0	B6.Cg-Becn1^tm2.1Blev Tg(APPV717F)109Ili	MGI:6257023
cx3	Apoe^tm1Unc/Apoe^tm1Unc Tg(APPV717F)109Ili/Tg(APPV717F)109Ili	involves: 129P2/OlaHsd	MGI:3721542
cx4	Apoe^tm1Unc/Apoe^tm1Unc Clu^tm1Jakh/Clu^tm1Jakh Tg(APPV717F)109Ili/Tg(APPV717F)109Ili	involves: 129P2/OlaHsd * 129S2/SvPas	MGI:3721541
cx5	Apoe^tm1Unc/Apoe^tm1Unc Tg(APPV717F)109Ili/0	involves: 129P2/OlaHsd * C57BL/6	MGI:3784385
cx6	Apoe^tm1Unc/Apoe^tm1Unc Tg(APPV717F)109Ili/0 Tg(GFAP-APOE_i4)#Hol/0	involves: 129P2/OlaHsd * C57BL/6 * CBA	MGI:3784383
cx7	Apoe^tm1Unc/Apoe^tm1Unc Tg(APPV717F)109Ili/0 Tg(GFAP-APOE_i3)37Hol/0	involves: 129P2/OlaHsd * C57BL/6 * CBA	MGI:3784384
cx8	Apoe^tm1Unc/Apoe^tm1Unc Tg(APPV717F)109Ili/0 Tg(GFAP-APOE_i2)14Hol/0	involves: 129P2/OlaHsd * C57BL/6 * CBA	MGI:3784387
cx9	Clu^tm1Jakh/Clu^tm1Jakh Tg(APPV717F)109Ili/Tg(APPV717F)109Ili	involves: 129S2/SvPas	MGI:3721530
cx10	Lrpap1^tm1Her/Lrpap1^tm1Her Tg(APPV717F)109Ili/0	involves: 129S7/SvEvBrd * C57BL/6 * DBA/2	MGI:3622696
cx11	Bcl2^tm1.1Sjk/Bcl2^tm1.1Sjk Tg(APPV717F)109Ili/0	involves: 129X1/SvJ * C57BL/6	MGI:6257027
cx12	Msr1^tm1Csk/Msr1^tm1Csk Tg(APPV717F)109Ili/?	involves: 129X1/SvJ * C57BL/6 * DBA/2 * ICR	MGI:2177120
cx13	Tg(APPV717F)109Ili/0 Tg(Prnp-MAPT*P301S)PS19Vle/0	involves: C3H * C57BL/6	MGI:5512698
cx14	Tg(APPV717F)109Ili/0 Tg(Prnp-Abca1)EHol/0	involves: C57BL/6 * CBA	MGI:3801011
cx15	Gt(ROSA)26Sor^tm3.1(CAG-SORL1)Tew/Gt(ROSA)26Sor^+ Tg(APPV717F)109Ili/0	Not Specified	MGI:5586992
tg16	Tg(APPV717F)109Ili/Tg(APPV717F)109Ili	Not Specified	MGI:3721531
tg17	Tg(APPV717F)109Ili/0	B6.Cg-Tg(APPV717F)109Ili	MGI:6257025
tg18	Tg(APPV717F)109Ili/0	involves: BALB/c * C57BL * C57BL/6NTac	MGI:5427915
tg19	Tg(APPV717F)109Ili/0	involves: C57BL/6 * DBA/2 * Swiss Webster	MGI:3718022
tg20	Tg(APPV717F)109Ili/0	Not Specified	MGI:2174818

Genotype
MGI:5427914

cn1

• Allelic Composition: Gsk3a^tm1.1Tac/Gsk3a^tm1.1Tac; Tg(APPV717F)109Ili/0; Tg(Camk2a-cre)#Stl/0
• Genetic Background: involves: BALB/c * C57BL * C57BL/6NTac

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

nervous system

amyloid beta deposits ( J:184975 )

• significant decrease in amyloid beta senile plaques compared to transgenic mice wild-type for Gsk3a

behavior/neurological

behavior/neurological phenotype ( J:184975 )

N • performance in a Barnes maze and in an open field are similar to wild-type controls unlike transgenic mice wild-type for Gsk3a

homeostasis/metabolism

amyloid beta deposits ( J:184975 )

• significant decrease in amyloid beta senile plaques compared to transgenic mice wild-type for Gsk3a

Genotype
MGI:6257023

cx2

• Allelic Composition: Becn1^tm2.1Blev/Becn1^tm2.1Blev; Tg(APPV717F)109Ili/0
• Genetic Background: B6.Cg-Becn1^tm2.1Blev Tg(APPV717F)109Ili

mortality/aging

extended life span ( J:244104 )

• mice exhibit decreased mortality compared to single Tg(APPV717F)109Ili expressing mice

Genotype
MGI:3721542

cx3

• Allelic Composition: Apoe^tm1Unc/Apoe^tm1Unc; Tg(APPV717F)109Ili/Tg(APPV717F)109Ili
• Genetic Background: involves: 129P2/OlaHsd

nervous system

amyloid beta deposits ( J:107702 )

• by 12 months of age, mice have amyloid beta (Abeta) deposits in the hippocampus and cortex

• deposits are diffuse in appearance; deposition is prominent in dentate hilus, but little or none in molecular layer of dentate gyrus

• at 12 months, mice have high levels of insoluble Abeta₄₂

increased cerebrospinal fluid amyloid beta 40 isoform level ( J:107702 )

• at 3 months, cerebrospinal fluid levels of Abeta₄₀ are elevated

increased cerebrospinal fluid amyloid beta 42 isoform level ( J:107702 )

• at 3 months, cerebrospinal fluid levels of Abeta₄₂ are elevated

homeostasis/metabolism

amyloid beta deposits ( J:107702 )

• by 12 months of age, mice have amyloid beta (Abeta) deposits in the hippocampus and cortex

• deposits are diffuse in appearance; deposition is prominent in dentate hilus, but little or none in molecular layer of dentate gyrus

• at 12 months, mice have high levels of insoluble Abeta₄₂

increased cerebrospinal fluid amyloid beta 40 isoform level ( J:107702 )

• at 3 months, cerebrospinal fluid levels of Abeta₄₀ are elevated

increased cerebrospinal fluid amyloid beta 42 isoform level ( J:107702 )

• at 3 months, cerebrospinal fluid levels of Abeta₄₂ are elevated

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
Alzheimer's disease		DOID:10652		J:107702

Genotype
MGI:3721541

cx4

• Allelic Composition: Apoe^tm1Unc/Apoe^tm1Unc; Clu^tm1Jakh/Clu^tm1Jakh; Tg(APPV717F)109Ili/Tg(APPV717F)109Ili
• Genetic Background: involves: 129P2/OlaHsd * 129S2/SvPas

nervous system

amyloid beta deposits ( J:107702 )

• at 6 months of age, most mice have substantial amyloid beta (Abeta) deposits

• by 12 months of age, mice have more amyloid beta (Abeta) deposits in the hippocampus and cortex than other genotypes

• Abeta deposits are more numerous and fill all parts of hippocampus and some of the cortex by 12 months; abundant compact and diffuse plaques are observed

• mice have greater levels of thioflavine-S-positive (fibrillar) Abeta deposits than other genotypes, similar to transgenic homozygotes with normal Apoe and Clu

increased cerebrospinal fluid amyloid beta 40 isoform level ( J:107702 )

• at 3 months, cerebrospinal fluid levels of Abeta₄₀ are elevated; Abeta₄₀ increase is greater than in transgenic, single Apoe-null mice

increased cerebrospinal fluid amyloid beta 42 isoform level ( J:107702 )

• at 3 months, cerebrospinal fluid levels of Abeta₄₂ are elevated

homeostasis/metabolism

amyloidosis ( J:107702 )

• mice have significant amyloid burden, greater than shown by other genotypes

• at 12 months, mice have highest tissue levels of soluble Abeta₄₀ and Abeta₄₂, with high levels of insoluble Abeta₄₂

• at 3 months, mice have higher levels of carbonate soluble Abeta₄₀ and Abeta₄₂ compared to other genotypes

amyloid beta deposits ( J:107702 )

• at 6 months of age, most mice have substantial amyloid beta (Abeta) deposits

• by 12 months of age, mice have more amyloid beta (Abeta) deposits in the hippocampus and cortex than other genotypes

• Abeta deposits are more numerous and fill all parts of hippocampus and some of the cortex by 12 months; abundant compact and diffuse plaques are observed

• mice have greater levels of thioflavine-S-positive (fibrillar) Abeta deposits than other genotypes, similar to transgenic homozygotes with normal Apoe and Clu

increased cerebrospinal fluid amyloid beta 40 isoform level ( J:107702 )

• at 3 months, cerebrospinal fluid levels of Abeta₄₀ are elevated; Abeta₄₀ increase is greater than in transgenic, single Apoe-null mice

increased cerebrospinal fluid amyloid beta 42 isoform level ( J:107702 )

• at 3 months, cerebrospinal fluid levels of Abeta₄₂ are elevated

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
Alzheimer's disease		DOID:10652		J:107702

Genotype
MGI:3784385

cx5

• Allelic Composition: Apoe^tm1Unc/Apoe^tm1Unc; Tg(APPV717F)109Ili/0
• Genetic Background: involves: 129P2/OlaHsd * C57BL/6

nervous system

amyloid beta deposits ( J:127846 , J:133058 )

• 40% of mice exhibit plaque depositions at 12 months of age with one mouse remaining plaque free at 21 months (J:127846)

• 23% of mice at 15 months, 33% at 18 months and 55% at 21 months exhibit fibrillar plaques in the outer molecular layer of the dentate gyrus (J:127846)

• mice exhibit plaques in the stratum oriens and radiatum of the hippocampus and hilus of the dentate gyrus (J:127846)

• 3 of 4 mice exhibit plaques by 12 months of age (J:133058)

homeostasis/metabolism

amyloid beta deposits ( J:127846 , J:133058 )

• 40% of mice exhibit plaque depositions at 12 months of age with one mouse remaining plaque free at 21 months (J:127846)

• 23% of mice at 15 months, 33% at 18 months and 55% at 21 months exhibit fibrillar plaques in the outer molecular layer of the dentate gyrus (J:127846)

• mice exhibit plaques in the stratum oriens and radiatum of the hippocampus and hilus of the dentate gyrus (J:127846)

• 3 of 4 mice exhibit plaques by 12 months of age (J:133058)

Genotype
MGI:3784383

cx6

• Allelic Composition: Apoe^tm1Unc/Apoe^tm1Unc; Tg(APPV717F)109Ili/0; Tg(GFAP-APOE_i4)#Hol/0
• Genetic Background: involves: 129P2/OlaHsd * C57BL/6 * CBA

nervous system

amyloid beta deposits ( J:127846 , J:133058 )

• by 15 to 18 months, 60% of mice exhibit plaques in the hippocampus (J:127846)

• the amount of amyloid deposited is more than in Tg(APPV717F)109Ili Tg(GFAP-APOE_i3)37Hol Apoe^tm1Unc/Apoe^tm1Unc mice but much less than in Tg(APPV717F)109Ili Apoe^tm1Unc/Apoe^tm1Unc mice (J:127846)

• plaques are observed in the outer molecular layer of the dentate gyrus and the stratum oriens and radiatum of the hippocampus (J:127846)

• mice exhibit fibrillar plaques in the outer molecular layer of the dentate gyrus (J:127846)

• 55.6% of mice exposed to traumatic brain injury (TBI) at 9 to 10 months of age exhibit amyloid plaques by 12 to 13 months of age while mice not exposed to TBI do not exhibit plaques until 15 months of age (J:133058)

• mice exhibit increased plaque formation and severity following TBI compared to in similarly treated Tg(APPV717F)109Ili Tg(GFAP-APOE_i3)37Hol Apoe^tm1Unc/Apoe^tm1Unc mice (J:133058)

• 44% of mice exhibit thioflavine-S+ amyloid staining (fibrillar amyloid) in the molecular layer unlike in Tg(APPV717F)109Ili Tg(GFAP-APOE_i3)37Hol Apoe^tm1Unc/Apoe^tm1Unc and Tg(APPV717F)109Ili Apoe^tm1Unc/Apoe^tm1Unc mice (J:133058)

homeostasis/metabolism

amyloid beta deposits ( J:127846 , J:133058 )

• by 15 to 18 months, 60% of mice exhibit plaques in the hippocampus (J:127846)

• the amount of amyloid deposited is more than in Tg(APPV717F)109Ili Tg(GFAP-APOE_i3)37Hol Apoe^tm1Unc/Apoe^tm1Unc mice but much less than in Tg(APPV717F)109Ili Apoe^tm1Unc/Apoe^tm1Unc mice (J:127846)

• plaques are observed in the outer molecular layer of the dentate gyrus and the stratum oriens and radiatum of the hippocampus (J:127846)

• mice exhibit fibrillar plaques in the outer molecular layer of the dentate gyrus (J:127846)

• 55.6% of mice exposed to traumatic brain injury (TBI) at 9 to 10 months of age exhibit amyloid plaques by 12 to 13 months of age while mice not exposed to TBI do not exhibit plaques until 15 months of age (J:133058)

• mice exhibit increased plaque formation and severity following TBI compared to in similarly treated Tg(APPV717F)109Ili Tg(GFAP-APOE_i3)37Hol Apoe^tm1Unc/Apoe^tm1Unc mice (J:133058)

• 44% of mice exhibit thioflavine-S+ amyloid staining (fibrillar amyloid) in the molecular layer unlike in Tg(APPV717F)109Ili Tg(GFAP-APOE_i3)37Hol Apoe^tm1Unc/Apoe^tm1Unc and Tg(APPV717F)109Ili Apoe^tm1Unc/Apoe^tm1Unc mice (J:133058)

Genotype
MGI:3784384

cx7

• Allelic Composition: Apoe^tm1Unc/Apoe^tm1Unc; Tg(APPV717F)109Ili/0; Tg(GFAP-APOE_i3)37Hol/0
• Genetic Background: involves: 129P2/OlaHsd * C57BL/6 * CBA

nervous system

amyloid beta deposits ( J:127846 , J:133058 )

• by 15 to 18 months, 31% of mice exhibit plaques in the hippocampus (J:127846)

• the amount of amyloid deposited is less than in Tg(APPV717F)109Ili Tg(GFAP-APOE_i4)#Hol Apoe^tm1Unc/Apoe^tm1Unc and much less than in Tg(APPV717F)109Ili Apoe^tm1Unc/Apoe^tm1Unc mice (J:127846)

• plaques are observed in the the outer molecular layer of the dentate gyrus and the stratum oriens and radiatum of the hippocampus (J:127846)

• mice exhibit fibrillar plaques in the outer molecular layer of the dentate gurys (J:127846)

• 20% of mice exposed to traumatic brain injury (TBI) at 9 to 10 months of age exhibit amyloid plaques by 12 to 13 months of age while mice not exposed to TBI do not exhibit plaques until 15 months of age (J:133058)

• mice exhibit decreased plaque formation and severity following TBI compared to in similarly treated Tg(APPV717F)109Ili Tg(GFAP-APOE_i4)#Hol Apoe^tm1Unc/Apoe^tm1Unc mice (J:133058)

homeostasis/metabolism

amyloid beta deposits ( J:127846 , J:133058 )

• by 15 to 18 months, 31% of mice exhibit plaques in the hippocampus (J:127846)

• the amount of amyloid deposited is less than in Tg(APPV717F)109Ili Tg(GFAP-APOE_i4)#Hol Apoe^tm1Unc/Apoe^tm1Unc and much less than in Tg(APPV717F)109Ili Apoe^tm1Unc/Apoe^tm1Unc mice (J:127846)

• plaques are observed in the the outer molecular layer of the dentate gyrus and the stratum oriens and radiatum of the hippocampus (J:127846)

• mice exhibit fibrillar plaques in the outer molecular layer of the dentate gurys (J:127846)

• 20% of mice exposed to traumatic brain injury (TBI) at 9 to 10 months of age exhibit amyloid plaques by 12 to 13 months of age while mice not exposed to TBI do not exhibit plaques until 15 months of age (J:133058)

• mice exhibit decreased plaque formation and severity following TBI compared to in similarly treated Tg(APPV717F)109Ili Tg(GFAP-APOE_i4)#Hol Apoe^tm1Unc/Apoe^tm1Unc mice (J:133058)

Genotype
MGI:3784387

cx8

• Allelic Composition: Apoe^tm1Unc/Apoe^tm1Unc; Tg(APPV717F)109Ili/0; Tg(GFAP-APOE_i2)14Hol/0
• Genetic Background: involves: 129P2/OlaHsd * C57BL/6 * CBA

nervous system

amyloid beta deposits ( J:127846 )

• 66% of mice exhibit plaques after 18 months

• mice exhibit plaques in the stratum oriens and radiatum of the hippocampus and hilus of the dentate gyrus but no the molecular layer of the dentate gyrus

• however, no fibrillar plaques are detected

homeostasis/metabolism

amyloid beta deposits ( J:127846 )

• 66% of mice exhibit plaques after 18 months

• mice exhibit plaques in the stratum oriens and radiatum of the hippocampus and hilus of the dentate gyrus but no the molecular layer of the dentate gyrus

• however, no fibrillar plaques are detected

Genotype
MGI:3721530

cx9

• Allelic Composition: Clu^tm1Jakh/Clu^tm1Jakh; Tg(APPV717F)109Ili/Tg(APPV717F)109Ili
• Genetic Background: involves: 129S2/SvPas

nervous system

amyloid beta deposits ( J:78357 , J:107702 )

• by 12 months of age, ~60% of mice show amyloid beta (Abeta) deposition (J:78357)

• decreased percentage of Abeta-immunoreactive deposits that are thioflavine-S-positive (2.46 vs 19.4% thioflavine load/Abeta load) compared to Clu-sufficient mice (J:78357)

• many Abeta deposits have few or no detectable dystrophic neurites around them (J:78357)

• by 12 months of age, mice have amyloid beta (Abeta) deposits in the hippocampus and cortex (J:107702)

abnormal neurite morphology ( J:78357 )

• a 10-fold reduction in dystrophic neurites in hippocampi at 12 months compared to Clu-sufficient transgenic mice and a 5-fold reduction in number of dystrophic neurites per amyloid deposit

homeostasis/metabolism

amyloidosis ( J:78357 )

• only 20% of mice have thioflavine-S-positive (fibrillar Abeta or amyloid) deposits in the cortex at 12 months

• mice have lower hippocampal amyloid burden (0.89%) at 12 months than Clu-sufficient transgenic mice; amyloid load increases to 2.25% by 15 months

amyloid beta deposits ( J:78357 , J:107702 )

• by 12 months of age, ~60% of mice show amyloid beta (Abeta) deposition (J:78357)

• decreased percentage of Abeta-immunoreactive deposits that are thioflavine-S-positive (2.46 vs 19.4% thioflavine load/Abeta load) compared to Clu-sufficient mice (J:78357)

• many Abeta deposits have few or no detectable dystrophic neurites around them (J:78357)

• by 12 months of age, mice have amyloid beta (Abeta) deposits in the hippocampus and cortex (J:107702)

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
Alzheimer's disease		DOID:10652		J:78357

Genotype
MGI:3622696

cx10

• Allelic Composition: Lrpap1^tm1Her/Lrpap1^tm1Her; Tg(APPV717F)109Ili/0
• Genetic Background: involves: 129S7/SvEvBrd * C57BL/6 * DBA/2

nervous system

amyloid beta deposits ( J:107567 )

• elevated amyloid deposits over controls

astrocytosis ( J:107567 )

• develop reactive astrocytosis

homeostasis/metabolism

amyloid beta deposits ( J:107567 )

• elevated amyloid deposits over controls

Genotype
MGI:6257027

cx11

• Allelic Composition: Bcl2^tm1.1Sjk/Bcl2^tm1.1Sjk; Tg(APPV717F)109Ili/0
• Genetic Background: involves: 129X1/SvJ * C57BL/6

mortality/aging

premature death ( J:244104 )

• mice show a trend of exacerbated mortality compared to single Tg(APPV717F)109Ili expressing mice

Genotype
MGI:2177120

cx12

• Allelic Composition: Msr1^tm1Csk/Msr1^tm1Csk; Tg(APPV717F)109Ili/?
• Genetic Background: involves: 129X1/SvJ * C57BL/6 * DBA/2 * ICR

nervous system

amyloid beta deposits ( J:58338 )

• number and distribution of plaques was similar to those seen in wild-type (Msr1+) mice heterozygous for Tg(APP)109Ili

neuron degeneration ( J:58338 )

• loss of synaptophysin-immunoreactive presynaptic terminals in the hippocampal outer molecular layer (loss was similar to that seen in wild-type (Msr1+) mice heterozygous for Tg(APP)109Ili )

• reduced density of MAP-2 immuoreactive neuronal dendrites in the outer molecular layer of the hippocampus (loss was similar to that seen in wild-type (Msr1+) mice heterozygous for Tg(APP)109Ili)

homeostasis/metabolism

amyloid beta deposits ( J:58338 )

• number and distribution of plaques was similar to those seen in wild-type (Msr1+) mice heterozygous for Tg(APP)109Ili

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
Alzheimer's disease		DOID:10652		J:58338

Genotype
MGI:5512698

cx13

• Allelic Composition: Tg(APPV717F)109Ili/0; Tg(Prnp-MAPT*P301S)PS19Vle/0
• Genetic Background: involves: C3H * C57BL/6

mortality/aging

premature death ( J:165441 )

• median survival of females and males is 12 and 10 months of age, respectively

• mutants exhibit a greater acceleration of death than single Tg(Prnp-MAPT*P301S)PS19Vle mice

growth/size/body

weight loss ( J:165441 )

• decrease in weight with increasing age

• males show a greater decrease in percentage of body weight than females

• mutants exhibit a greater acceleration weight loss than single Tg(Prnp-MAPT*P301S)PS19Vle mice

behavior/neurological

paralysis ( J:165441 )

• 56% of mutants exhibit paresis or paralysis and presence of a hunchback posture at 11 months of age

• males show a more profound motor phenotype than females

• mutants exhibit a greater acceleration of motor phenotype than single Tg(Prnp-MAPT*P301S)PS19Vle mice

paresis ( J:165441 )

• 56% of mutants exhibit paresis or paralysis and presence of a hunchback posture at 11 months of age

nervous system

amyloid beta deposits ( J:165441 )

• limited amyloid beta deposits are seen at 8 months of age within the corpus callosum, stratum oriens, and radiatum of CA1, visual cortex, molecular layer of the dentate gyrus, and retrosplenial area

• at 11 months of age, an increase in amyloid beta deposition is seen in the same areas as at 8 months of age

• mutants exhibit an increase in plaque load with increasing age from 8 to 11 months of age for the anterior and posterior hippocampus

• most amyloid beta deposits are not composed of amyloid beta species that are assembled into ThS-positive amyloid fibrils

neurofibrillary tangles ( J:165441 )

• mutants develop ThS-positive neurofibrillary tangles at a much earlier age than single Tg(Prnp-MAPT*P301S)PS19Vle mice

• a greater proportion of double mutants develop tangles at 8 and 11 months of age than single Tg(Prnp-MAPT*P301S)PS19Vle mice

tau protein deposits ( J:165441 )

• mutants exhibit an accelerated progression in the distribution of abnormally phosphorylated tau from the entorhinal and neocortex, followed by involvement of the hippocampal formation and subcortical structures, to finally penetration of all layers of the neocortex compared to single Tg(Prnp-MAPT*P301S)PS19Vle mice

neurodegeneration ( J:165441 )

• substantial loss of neurons that secrete amyloid beta

skeleton

kyphosis ( J:165441 )

• 56% of mutants exhibit paresis or paralysis and presence of a hunchback posture at 11 months of age

homeostasis/metabolism

amyloid beta deposits ( J:165441 )

• limited amyloid beta deposits are seen at 8 months of age within the corpus callosum, stratum oriens, and radiatum of CA1, visual cortex, molecular layer of the dentate gyrus, and retrosplenial area

• at 11 months of age, an increase in amyloid beta deposition is seen in the same areas as at 8 months of age

• mutants exhibit an increase in plaque load with increasing age from 8 to 11 months of age for the anterior and posterior hippocampus

• most amyloid beta deposits are not composed of amyloid beta species that are assembled into ThS-positive amyloid fibrils

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
Alzheimer's disease		DOID:10652		J:165441

Genotype
MGI:3801011

cx14

• Allelic Composition: Tg(APPV717F)109Ili/0; Tg(Prnp-Abca1)EHol/0
• Genetic Background: involves: C57BL/6 * CBA

nervous system

amyloid beta deposits ( J:131400 )

• at 12 months, rare amyloid beta (Abeta) deposits are observed in the cortex, with occasional deposits in the molecular layer of hippocampus and frequent Abeta deposits in the hilus of the dentate gyrus; mice show 3-fold less Abeta in the brain relative to Tg(APPV717F)109Ili, Abca1-wild-type controls

• fibrillar Abeta plaques are frequently observed in cortex and hippocampus

• Abeta deposits are almost all diffuse, with little true amyloid

• very few clusters of reactive microglia are seen in brain

homeostasis/metabolism

amyloid beta deposits ( J:131400 )

• at 12 months, rare amyloid beta (Abeta) deposits are observed in the cortex, with occasional deposits in the molecular layer of hippocampus and frequent Abeta deposits in the hilus of the dentate gyrus; mice show 3-fold less Abeta in the brain relative to Tg(APPV717F)109Ili, Abca1-wild-type controls

• fibrillar Abeta plaques are frequently observed in cortex and hippocampus

• Abeta deposits are almost all diffuse, with little true amyloid

• very few clusters of reactive microglia are seen in brain

Genotype
MGI:5586992

cx15

• Allelic Composition: Gt(ROSA)26Sor^{tm3.1(CAG-SORL1)Tew}/Gt(ROSA)26Sor⁺; Tg(APPV717F)109Ili/0
• Genetic Background: Not Specified

nervous system

abnormal nervous system morphology ( J:213687 )

• mice show reduced concentrations of human amyloid beta40 and amyloid beta42 peptides in cortical and hippocampal extracts

• however, basal concentrations of brain interstitial fluid amyloid beta40 are unchanged in the brain parenchyma of adults compared to single Tg(APPV717F)109Ili mice

• concentrations of the soluble human APP alpha and APP beta are not affected

Genotype
MGI:3721531

tg16

• Allelic Composition: Tg(APPV717F)109Ili/Tg(APPV717F)109Ili
• Genetic Background: Not Specified

nervous system

amyloid beta deposits ( J:78357 , J:107702 )

• by 12 months of age, ~60% of mice show amyloid beta (Abeta) deposition (J:78357)

• mice have a higher percentage of thioflavine-S positive Abeta-immunoreactive deposits than Clu-null mice (J:78357)

• all deposits are surrounded by multiple enlarged, dystrophic neurites (J:78357)

• a 2-fold increase in monomeric Abeta is detected in the brain compared to Clu-deficient transgenic mice (J:78357)

• by 12 months of age, mice have amyloid beta (Abeta) deposits in the hippocampus and cortex (J:107702)

• mice have prominent deposits that are both diffuse and compact in appearance in hippocampus and in molecular layer of dentate gyrus (J:107702)

abnormal neurite morphology ( J:78357 )

• dystrophic neurites are 10-fold higher compared to Clu-null transgenic mice and more dystrophic neurites (5-fold) are associated with each amyloid deposit

homeostasis/metabolism

amyloidosis ( J:78357 )

• 77% of mice have thioflavine-S-positive (fibrillar Abeta or amyloid) deposits in the cortex

• hippocampal amyloid burden is greater (2.76%) than in Clu-null transgenics at 12 months of age

amyloid beta deposits ( J:78357 , J:107702 )

• by 12 months of age, ~60% of mice show amyloid beta (Abeta) deposition (J:78357)

• mice have a higher percentage of thioflavine-S positive Abeta-immunoreactive deposits than Clu-null mice (J:78357)

• all deposits are surrounded by multiple enlarged, dystrophic neurites (J:78357)

• a 2-fold increase in monomeric Abeta is detected in the brain compared to Clu-deficient transgenic mice (J:78357)

• by 12 months of age, mice have amyloid beta (Abeta) deposits in the hippocampus and cortex (J:107702)

• mice have prominent deposits that are both diffuse and compact in appearance in hippocampus and in molecular layer of dentate gyrus (J:107702)

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
Alzheimer's disease		DOID:10652		J:78357

Genotype
MGI:6257025

tg17

• Allelic Composition: Tg(APPV717F)109Ili/0
• Genetic Background: B6.Cg-Tg(APPV717F)109Ili

mortality/aging

premature death ( J:244104 )

• mice exhibit higher early mortality than wild-type mice, starting at 2 months of age

nervous system

amyloid beta deposits ( J:244104 )

• mice exhibit extracellular amyloid deposition starting at 6-9 months of age

homeostasis/metabolism

amyloid beta deposits ( J:244104 )

• mice exhibit extracellular amyloid deposition starting at 6-9 months of age

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
Alzheimer's disease		DOID:10652		J:244104

Genotype
MGI:5427915

tg18

• Allelic Composition: Tg(APPV717F)109Ili/0
• Genetic Background: involves: BALB/c * C57BL * C57BL/6NTac

nervous system

amyloid beta deposits ( J:184975 )

behavior/neurological

abnormal spatial learning ( J:184975 )

• significant deficits in latency to find the target on the Barnes maze and use a poor maze strategy

increased locomotor activity ( J:184975 )

• increase in locomotor activity in an open field

homeostasis/metabolism

amyloid beta deposits ( J:184975 )

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
Alzheimer's disease		DOID:10652		J:184975

Genotype
MGI:3718022

tg19

• Allelic Composition: Tg(APPV717F)109Ili/0
• Genetic Background: involves: C57BL/6 * DBA/2 * Swiss Webster

nervous system

nervous system phenotype ( J:100974 )

N • mice do not show neuronal loss in the hippocampal regions compared to Tg(PDGFB-APP*V717F)H6Lms mice

Genotype
MGI:2174818

tg20

• Allelic Composition: Tg(APPV717F)109Ili/0
• Genetic Background: Not Specified

nervous system

amyloid beta deposits ( J:23080 , J:127846 , J:165441 )

• deposits of human beta-amyloid are seen in the hippocampus, corpus callosum and cerebral cortex, beginning at 6 - 9 months, and increasing in density with age (J:23080)

• mice develop plaques by 12 months of age in the hippocampus and the outer molecular layer of the dentate gyrus with a subset of plaques positive for fibrillar amyloid (J:127846)

• plaque deposition increases with age with greater than 85% of the hippocampus covered in plaques at 24 months of age (J:127846)

abnormal dentate gyrus morphology ( J:23080 )

• synaptic and dendritic density are reduced in the molecular layer

neurofibrillary tangles ( J:23080 )

• amyoid plaques are associated with distorted neurites

gliosis ( J:23080 )

• the majority of amyloid plaques are surrounded by GFAP-positive reactive astrocytes

homeostasis/metabolism

amyloid beta deposits ( J:23080 , J:127846 , J:165441 )

• deposits of human beta-amyloid are seen in the hippocampus, corpus callosum and cerebral cortex, beginning at 6 - 9 months, and increasing in density with age (J:23080)

• mice develop plaques by 12 months of age in the hippocampus and the outer molecular layer of the dentate gyrus with a subset of plaques positive for fibrillar amyloid (J:127846)

• plaque deposition increases with age with greater than 85% of the hippocampus covered in plaques at 24 months of age (J:127846)

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
Alzheimer's disease		DOID:10652		J:23080